DMAC DiaMedica Therapeutics Inc.

3.58
+0.06  (+2%)
Previous Close 3.52
Open 3.49
Price To Book 32.55
Market Cap 42805609
Shares 11,956,874
Volume 23,730
Short Ratio
Av. Daily Volume 76,555

NewsSee all news

  1. DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
  2. DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
  3. OTC Markets Group Announces Quarterly Index Performance and Rebalancing
  4. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  5. DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019 or 1Q 2020.
DM199 - Remedy
Acute ischaemic stroke
Phase 2 trial to be initiated 2019/2020.
DM199
Vascular dementia
Phase 1b dosing of first patient announced February 14, 2019.
DM199
Chronic Kidney Disease

Latest News

  1. DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
  2. DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
  3. OTC Markets Group Announces Quarterly Index Performance and Rebalancing
  4. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  5. DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
  6. UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
  7. IPO Outlook For The Week: Proteins, Fashion And Finance